Escitalopram for Kids’ Anxiety: FDA Approval or Risky Gamble? Weighing the Evidence”
From Pharmacology News by Circle Of Insight Productions
June 8, 2026 · 8 min
About this episode
This episode discusses the FDA's approval of escitalopram for children's anxiety and the associated risks and benefits.
In 2023, the FDA approved escitalopram (Lexapro) for generalized anxiety disorder (GAD) in children aged 7 and older, based largely on one industry-sponsored trial showing a small statistical edge over placebo on the Pediatric Anxiety Rating Scale (PARS). Critics argue the benefits fall below clinically meaningful thresholds while risks—particularly a roughly six-fold increase in treatment-emergent suicidal ideation—raise serious concerns about the risk-benefit balance. This episode explores the trial data, study limitations, broader context of pediatric antidepressant use, and what it means for families and clinicians navigating anxiety treatment options.
Topics covered
- pediatric anxiety treatment
- FDA approval
- escitalopram
- risk-benefit analysis
- mental health
- antidepressants
Keywords
- escitalopram
- Lexapro
- FDA approval
- children's anxiety
- GAD
- suicidal ideation
- PARS
- antidepressants
- mental health
- treatment options
Mentioned in this episode
Organizations: FDA, Pediatric Anxiety Rating Scale (PARS)
Products: escitalopram, Lexapro
More episodes of Pharmacology News
- Retracted: The Hepatitis B Vaccine, Autism Claims, and the Challenges of Causation · June 9, 2026 · 7 min
- Noribogaine (DMX-1001): A Neuroplastogen Breakthrough for Alcohol Use Disorder or Another Psychedelic Promise with Risks? · June 1, 2026 · 5 min
- Rising Costs in Healthcare: The 2026 Pharmaceutical Price Increases and Their Implications · May 27, 2026 · 5 min
- The Accidental Mind: Serendipity and the Birth of Modern Psychopharmacology part 2 · May 26, 2026 · 5 min
- The Accidental Mind: Serendipity and the Birth of Modern Psychopharmacology part 1 · May 25, 2026 · 4 min
- Curcumin: Turmeric’s Golden Promise for Blood Sugar and Mood – Evidence, Arguments For and Against · May 21, 2026 · 6 min
Explore listener stats, chart rankings, contacts and more on the Pharmacology News podcast page.